Abstract
Parkinson disease (PD) is a progressive neurodegenerative syndrome that affects motor and nonmotor abilities. This manufacturer-funded study addressed the safety, tolerability, and efficacy of bilateral intrastriatal delivery of ProSavin, a lentiviral vector–based gene therapy intended to enhance continuous dopamine production in the brain. The study was a phase 1/2 open-label trial with an open-label follow-up for safety. Fifteen patients with mild-to-moderate PD and a well-documented response to dopamine therapy received low-dose (1·9×107 transducing units [TU]; 3 patients), mid-dose …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
